NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free VTYX Stock Alerts $4.22 +0.10 (+2.43%) (As of 01:57 PM ET) Add Compare Share Share Today's Range$4.17▼$4.4350-Day Range$3.74▼$10.1352-Week Range$1.87▼$40.58Volume331,620 shsAverage Volume3.27 million shsMarket Capitalization$297.51 millionP/E RatioN/ADividend YieldN/APrice Target$21.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ventyx Biosciences alerts: Email Address Ventyx Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside409.4% Upside$21.75 Price TargetShort InterestBearish14.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 8 Articles This WeekInsider TradingSelling Shares$39,787 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.55) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.94 out of 5 starsMedical Sector963rd out of 2,771 stocksPharmaceutical Preparations Industry425th out of 1,288 stocks 3.3 Analyst's Opinion Consensus RatingVentyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageVentyx Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Ventyx Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.79% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently increased by 0.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTYX. Previous Next 3.3 News and Social Media Coverage News SentimentVentyx Biosciences has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for VTYX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows5 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,787.00 in company stock.Percentage Held by Insiders24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ventyx Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ventyx Biosciences are expected to grow in the coming year, from ($2.55) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ventyx Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Millionaire Says: “Buy This $11 AI Coin.”Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos.Find out more about this $11 AI Coin right now About Ventyx Biosciences Stock (NASDAQ:VTYX)Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.Read More VTYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTYX Stock News HeadlinesMay 13 at 8:35 PM | finance.yahoo.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | markets.businessinsider.comBuy Rating for Ventyx Biosciences Based on Clinical and Financial StrengthsMay 9, 2024 | investorplace.comVTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comVentyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate ProgressMay 8, 2024 | americanbankingnews.comVentyx Biosciences (VTYX) Set to Announce Quarterly Earnings on ThursdayMay 6, 2024 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of "Moderate Buy" from AnalystsMay 2, 2024 | globenewswire.comVentyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024April 30, 2024 | prnewswire.comVTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXApril 30, 2024 | markets.businessinsider.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesApril 29, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)April 29, 2024 | prnewswire.comVTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXApril 29, 2024 | markets.businessinsider.comUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYXApril 27, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesApril 27, 2024 | stockhouse.comVTYX FINAL DEADLINE ALERT: Bernstein Liebhard LLP Reminds Ventyx Biosciences, Inc. Investors of Upcoming DeadlineApril 26, 2024 | prnewswire.comThe Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYXApril 25, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx BiosciencesApril 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the FirmApril 23, 2024 | prnewswire.comVTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud LawsuitApril 22, 2024 | markets.businessinsider.comUPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the FirmApril 22, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of VentyxApril 22, 2024 | prnewswire.comLevi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming DeadlineApril 21, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of VentyxApril 21, 2024 | prnewswire.comVTYX IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYXSee More Headlines Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VTYX CUSIPN/A CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees79Year FoundedN/APrice Target and Rating Average Stock Price Target$21.75 High Stock Price Target$62.00 Low Stock Price Target$5.00 Potential Upside/Downside+409.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.20% Return on Assets-60.62% Debt Debt-to-Equity RatioN/A Current Ratio11.87 Quick Ratio11.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book1.03Miscellaneous Outstanding Shares70,500,000Free Float53,304,000Market Cap$301.04 million OptionableOptionable Beta0.48 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Sheila K. Gujrathi M.D. (Age 54)Executive Chairperson Comp: $125kDr. Raju S. Mohan Ph.D. (Age 66)Founder, CEO, President & Director Comp: $905.29kDr. John M. Nuss Ph.D. (Age 65)Chief Scientific Officer Comp: $630.63kDr. Martin Douglas Auster M.D. (Age 49)Chief Financial Officer Key CompetitorsVerrica PharmaceuticalsNASDAQ:VRCAKamadaNASDAQ:KMDAOrganogenesisNASDAQ:ORGOCorMedixNASDAQ:CRMDNeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 36,453 shares on 5/10/2024Ownership: 5.256%Bleakley Financial Group LLCSold 3,177 shares on 5/8/2024Ownership: 0.042%Mirae Asset Global Investments Co. Ltd.Bought 13,169 shares on 5/1/2024Ownership: 0.019%Norden Group LLCBought 10,685 shares on 4/30/2024Ownership: 0.015%China Universal Asset Management Co. Ltd.Bought 4,553 shares on 4/29/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions VTYX Stock Analysis - Frequently Asked Questions Should I buy or sell Ventyx Biosciences stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VTYX shares. View VTYX analyst ratings or view top-rated stocks. What is Ventyx Biosciences' stock price target for 2024? 9 analysts have issued 12-month price objectives for Ventyx Biosciences' stock. Their VTYX share price targets range from $5.00 to $62.00. On average, they expect the company's stock price to reach $21.75 in the next year. This suggests a possible upside of 409.4% from the stock's current price. View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts. How have VTYX shares performed in 2024? Ventyx Biosciences' stock was trading at $2.47 at the beginning of the year. Since then, VTYX stock has increased by 72.9% and is now trading at $4.27. View the best growth stocks for 2024 here. When is Ventyx Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our VTYX earnings forecast. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) released its earnings results on Thursday, May, 9th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. During the same period in the prior year, the business posted ($0.68) earnings per share. When did Ventyx Biosciences IPO? Ventyx Biosciences (VTYX) raised $152 million in an initial public offering on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share. Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.26%), Bleakley Financial Group LLC (0.04%), Simplicity Wealth LLC (0.04%), Mirae Asset Global Investments Co. Ltd. (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and Norden Group LLC (0.02%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VTYX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.